about
Thrombocytopenia and perioperative complications after stentless Freedom Solo valve implantation.Thrombocytopenia associated with TAVI-The summary of possible causes.The causes of thrombocytopenia after transcatheter aortic valve implantation.Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis.To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients.Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.Secondary acute lymphoblastic leukaemia in a multiple myeloma patient.Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.Plasma concentration of protein Z and protein Z-dependent protease inhibitor in patients with haemophilia A.Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group.Assessment of expression of selected Bcl-2 family proteins in lymphoid infiltration in patients with B-cell chronic lymphocytic leukaemia treated with nucleoside analogues.Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients.Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patientsProtein Z Concentrations in Patients With Acute LeukemiaProtein Z concentration in multiple myeloma patientsEvaluation of TNF superfamily molecules release by neutrophils and B leukemic cells of patients with chronic B - cell lymphocytic leukemiaEvaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresisTreatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group studyExpression of IL-1 and IL-6 and their natural regulators in leukocytes of B-cell chronic lymphocytic leukaemia patients
P50
Q33408555-2BEDD099-C707-43E7-8BAB-37A4F2A033EEQ33442175-2FD4BA83-00DB-4564-8BD0-6B03AAB36D02Q33442446-30EE6285-18A8-4D21-9F68-06F531387DEDQ35167926-A09CED28-C5AC-4FC3-BE8B-2EE949B59EFAQ37225538-751A9E13-AE44-404E-B18A-517FCC5A900DQ40373192-10527259-C2B6-4A5D-B6B3-7F246641625FQ40775213-5BFCC9A9-5CE6-4D8F-B575-4D50DB8BBCD6Q42971621-2AC8F672-3C14-46BB-BF8E-C47775A07026Q43121136-6ECE91D0-628F-493F-B111-335F28B19699Q43138104-F3715112-8C5C-416D-B49D-4B6D3BAD9FC7Q43281442-6CE953DD-8E0C-4B4D-8978-49FA69A21DC7Q44103497-4348A275-93BE-4A44-96D1-52C0B01C7482Q45883976-76CCE312-23FB-4F9D-B00E-B4665243CD66Q46084649-4BBAEBBA-4CAF-4BFF-A0F5-EFE139F568D5Q46213982-5F53CFA7-E00B-4A62-BD13-705CC9DEA55DQ46540779-D845180E-B94E-4D1B-8D78-EAC488155B56Q61943533-31E00F9F-C2F1-4C3E-8165-0DED59533315Q62590214-8630DC8A-91DE-4D2F-B3AE-8E4F868AD595Q62590216-DBCCC3D5-5EDA-4700-BE62-908137C67227Q82410785-76FF47E3-460B-4F4E-8C04-F61B157F0637Q82582443-AD23B1F9-99B2-4C84-BD24-B5962AF9C528Q85956565-5DAC3C81-73AB-42E0-8392-5A5FA237879CQ87291251-4BDAF0CF-09B5-49A4-9556-649E51704631
P50
description
researcher ORCID ID = 0000-0001-7586-8726
@en
wetenschapper
@nl
name
Jaroslaw Piszcz
@ast
Jaroslaw Piszcz
@en
Jaroslaw Piszcz
@es
Jaroslaw Piszcz
@nl
type
label
Jaroslaw Piszcz
@ast
Jaroslaw Piszcz
@en
Jaroslaw Piszcz
@es
Jaroslaw Piszcz
@nl
prefLabel
Jaroslaw Piszcz
@ast
Jaroslaw Piszcz
@en
Jaroslaw Piszcz
@es
Jaroslaw Piszcz
@nl
P214
P106
P1153
7801486539
P214
P31
P496
0000-0001-7586-8726
P7859
viaf-315235750